Guillermo de Velasco

3PUBLICATIONS
42CO-AUTHORS
Predictive and prognostic markersMolecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Sep 28, 2026
Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study).

|Apr 29, 2025
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.

Juan F Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández

|Feb 12, 2025
AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors.

Lillian L Siu, Sophie Postel-Vinay, Rafael Villanueva-Vázquez

Pageof 1

Frequent Collaborators

1 joint publications

Lillian L Siu

1 joint publications

Sophie Postel-Vinay

1 joint publications

Rafael Villanueva-Vázquez

1 joint publications

Eduardo Castanon Alvarez